This is to announce that the new INCA President is Catherine Bouvier, Co-Founder and CEO of Neuroendocrine Cancer UK.
This month, Simone Leyden’s term as INCA President came to an end and she passed the torch to Catherine Bouvier, who has officially assumed office. INCA is incredibly thankful for Simone’s instrumental leadership which has led to amazing progress, achievements and new milestones reached for the organization during her term in the past two years. Her successor is very much focused on building on this momentum.
Here are a few words from the new INCA President:
“I am honored to be given the opportunity to drive forward the ongoing work of the organization.
During my term as INCA President, I hope to see growth across all our 3 strategic pillars through truly collaborative cross functional working. This will lead to improving impact and outcomes for patients who follow a less common pathway, establishing patient experience as being on a par with clinical effectiveness and safety, the provision of standardized, useful and accurate patient information, an increase in patient driven research, our membership, education and awareness across this diverse and complex disease area.
INCA is the global voice and umbrella organization for the Neuroendocrine Cancer and Genetic Neuroendocrine Tumor Community, recognizing the exceptional work done nationally/locally by both our membership organizations and individual patient advocates.
As the well-known saying goes: ‘if you want to go fast, go alone, but if you want to go far, go together’, and I very much intend for a united approach, and look forward to working with each and every one of you to improve outcomes for all.”, says Catherine Bouvier, Co-Founder and CEO of Neuroendocrine Cancer UK.
With the committed leadership of Catherine Bouvier and a strong and dedicated Board of Directors, INCA will continue to work to make a difference for the NET community.